---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-004189"
form_type: "8-K/A"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:16:14.612849+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development

## Summary
- Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.
- Annual base salary of $450,000; target performance bonus of 45% of base salary.
- Special milestone bonuses: $100,000 after 60 days, $100,000 after 120 days.
- Granted option to purchase 125,000 ADSs vesting over 4 years (25% annual, rest monthly).
- Employment is at-will; governed by New York law with mandatory arbitration.

## SEC filing metadata
- accession: 0001178913-22-004189
- form_type: 8-K/A
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/0001178913-22-004189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004189/zk2228824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-004189
- JSON: https://secwatch.observer/filing/0001178913-22-004189.json
- Plain text: https://secwatch.observer/filing/0001178913-22-004189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.